BCRX BIOCRYST PHARMACEUTICALS INC

Price Chart

Executive Summary

BioCryst held its 2026 Annual Meeting on June 11, 2026, where shareholders approved an amendment to the Stock Incentive Plan to increase shares available by 7 million, ratified Ernst & Young as auditor, and elected three directors. The plan amendment passed with 119.8 million votes for and 63.3 million against (65.4% approval of votes cast). This is a routine governance event with no material financial impact, as the additional shares simply replenish the equity compensation pool for future awards to employees and directors.

Actionable Insight

Key Facts

• Shareholders approved an amendment to the Stock Incentive Plan to increase the number of shares available for issuance by 7,000,000 shares.
• Total shares available under the Plan as of April 20, 2026, was 61,000,333 (including 46,287,133 already issued, 7,713,200 available, and the 7,000,000 increase).
• Maximum shares issuable over the Plan's term is 88,090,000.
• The Plan includes a 12-month minimum vesting period for awards (with exceptions for death, disability, or change in control, and for up to 5% of shares).
• Each non-employee director is subject to an annual compensation cap of $750,000 ($1,000,000 for first-year directors).
• The three director nominees (Theresa M. Heggie, Amy E. McKee, Jon P. Stonehouse) were elected with strong support (96-98% of votes cast in favor, excluding broker non-votes).
• Ratification of Ernst & Young as independent auditor passed with 96.5% of votes cast in favor.
• Advisory vote on executive compensation passed with 68.9% of votes cast in favor, though with significant opposition (31.1% against).

Financial Impact

No direct financial impact. The 7 million-share increase (approximately 3.2% of shares outstanding at current share count, assuming ~217M shares outstanding) expands the equity pool for future compensation grants but does not represent immediate dilution or cash cost.

Risk Factors

• The Incentive Plan Proposal received 34.6% of votes cast against, indicating notable opposition from some shareholders.
• Increased equity compensation could gradually dilute existing shareholders if large grants are made under the replenished share pool.
• Advisory say-on-pay vote of 68.9% is below 70% threshold that some governance watchdogs consider a red flag, though not material.
• Broker non-votes of 34 million (approx. 18% of outstanding) on the incentive plan and say-on-pay reflect passive institutional block.

Market Snapshot

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

US Market Status